Viva Biotech Unveils Breakthrough in Cyclic Peptide Therapeutics, Paving the Way for Drug Discovery Innovation
Reuters
Sep 02
<a href="https://laohu8.com/S/01873">Viva Biotech</a> Unveils Breakthrough in Cyclic Peptide <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Paving the Way for Drug Discovery Innovation
Viva Biotech Holdings has announced significant advancements in the field of cyclic peptide therapeutics, emphasizing their potential to bridge the gap between small molecules and large biologics. The company's integrated platform for peptide drug discovery and development, which spans from hit discovery to preclinical candidates, has delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with a focus on cyclic peptides. These advancements have already been presented, highlighting the use of AI-enabled peptide design, DEL screening, and phage display in the discovery process. With an emphasis on cyclic peptides' ability to target traditionally "undruggable" protein-protein interactions, Viva Biotech aims to continue collaborating with global partners to translate these innovations into real-world therapeutics.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: EN63159) on September 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.